















































































































































































































Intracrine	machinery	 Cornea Conjunctiva Meibomian	gland	 Lacrimal	gland
Receptor	 	 	
AR	 			+	([39],[40]) +	([39]) 		+	([39,41,42],)	 +	([39])
ER	 +	([40]) +	([43]) +	([41,44])	 +	([45])
PR	 +	([40]) +	([43]) +	([41,44])	 +	([45])
AR	mRNA	 				+	(	[46],[40]) +	([46]) +	([46])	 +	([46])
ER	mRNA	 			+	([46],[40]) 					+	([46],[43],[47]) +	([46])	 		+	([46],[47])
PR	mRNA	 			+	([46],[40]) 		+	([46],[43]) +	([46])	 +	([46])
Enzyme	mRNA	 	 	













































































































































































F=1  1.5% DHEA drops / 3 weeks N  Improved symptoms, But and lipid layer, reduced 
Schirmer’s 
Worda et al 2001* [75] M=1  3% Testos cream t.i.d. 3 months N  Improved symptoms and lipid layer, restored tear film 
Connor, et al 2001 [Conference][76]  F=1, M=9 1% DHEA drops q.i.d. 2 weeks Y  Improved symptoms, Schirmer’s and TBUT
Connor 2002 [Conference] [77] F=15, M=5 2.5% Testos cream b.i.d. 3 weeks Y  Improved symptoms and Schirmer’s
Connor , et al 2002[Conference] [78]  F=9, M=11 1% Testos, 
1% DHEA drops 
q.i.d. 2 weeks Y  DHEA improved BUT & Schirmer’s
Testos decreased Schirmer’s 
US Patent No 6659985 B2, 2003[79]  F=4, M=1 2.5% DHEA cream t.i.d. 2 weeks N  Improved symptoms & CL WT.  Improved  Schirmer’s 
and TBUT in male subject only  
F=2  2.5% Testos cream b.i.d. 2 weeks N  Improved symptoms , CL WT, Schirmer’s and BUT  
Connor 2003 [Conference][80] F=25, M=3 3% Testos cream b.i.d. 2 weeks Y  Improved symptoms and Schirmer’s
Schiffman 2006[Conference] [81]  179  0.01%, 0.03%, 
0.1% Testos 
/ 6 months Y  Improved MG secretions
Connor 2007[Conference] [82]   F=40, M=10 5% Testos, 
20% Prog cream 
b.i.d. / N  Improved symptoms and TBUT




q.i.d. 2 months Other eye Improved symptoms
US Patent No 6096733, 1998 [85]  F=45  0.1%, 0.25% E2 
drops 
q.i.d. 90 days Y  Improved symptoms and TBUT
F  0.05% E2 drops t.i.d. 10 days Other eye Maturation conjunctival epithelium 
Akramanian et al * 1997 & 1998 [86,87]  F=20  3% E2 ointment / 1 week Y  Improved symptoms, Schirmer’s and TBUT
Sator et al* 1998[88] F=84  0.025% E2 drops q.i.d. 4 months Y  Improved symptoms and Schirmer’s
Abbreviations: *indicates published studies, [Conference]: conference proceedings, F: Female, M: Male, Testos : testosterone, Prog: progesterone, E2: Estradiol, /: unknown, b.i.d: twice 
daily, t.i.d. three times daily, q.i.d. four times daily, Y: yes, N: no,  CL WT: contact lens wearing time, TBUT; tear break up time, MG: meibomian gland. 
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In	summary,		eye	drops	and	cream	applied	to	the	eyelids,	supplemented	with	
testosterone	or	DHEA	have	a	beneficial	effect	on	symptoms,	tear	stability	and	
quantity.[75,77,80,83],[74,78]	However,	evidence	is	weak	with	an	absence	of	placebo	
controlled	published	studies	which		are	required	to	improve	our	understanding	of	the	
possible	application	of	topical	androgens	for	clinical	treatment	of	dry	eye.		
There	are	a	very	limited	number	of	studies	researching	the	effect	of	estradiol	therapy	on	
dry	eye,	including	only	two	published	controlled	studies,	one	of	which	has	many	
possible	confounding	factors.[88]		Evidence	seems	to	suggest	that	topical	estradiol	may	
be	beneficial	for	the	treatment	of	dry	eye.	This	is	in	agreement	with	studies	which	found	
systemic	estrogen	treatment	to	improve	dry	eye,[87–93]		but	disagrees	with	studies	
which	found	systemic	estrogen	therapy	to	exacerbate	dry	eye.[94–96]	Although	
systemic	estrogen	therapy	has	conflicting	results,	the	limited	results	from	studies	of	
topical	estradiol	therapy	(including	preliminary	studies)	suggest	a	positive	effect	of	
topical	treatment,	which	may	be	more	associated		with	local	synthesis	of	sex	
hormones.[24]		
Topical	estrogen	and	androgen	therapy	appears	to	have	a	positive	effect	on	signs	and	
symptoms	of	dry	eye;	however	published	evidence	is	weak	with	the	majority	of	studies	
being	preliminary.		
IV. SUMMARY	
This	review	aimed	to	provide	a	comprehensive	discussion	focussed	on	the	impact	of	
local	sex	hormone	synthesis	on	dry	eye.	It	was	necessary	to	discuss	the	wider	topic	of	
intracrinology	before	focussing	on	ocular	structures.		Despite	the	increase	in	knowledge	
of	local	hormone	synthesis,	much	of	the	recent	literature	focusses	on	the	effects	of	
circulating,	rather	than	local,	sex	hormones	on	signs	or	symptoms	of	dry	eye.	This	is	
likely	due	to	the	relative	ease	of	systemic	measurement	in	comparison	to	local.		
Much	research	regarding	sex	hormones	and	the	ocular	surface	has	been	performed	on	
rats	and	mice	to	show	the	presence	of	sex	hormone	mRNA	in,	ocular	structures;	the	
meibomian	and	lacrimal	glands	have	been	of	particular	interest	in	published	research	to	
date,	likely	due	to	their	role	in	tear	formation.	Labrie	describes	intracrinology	as	“the	
formation	of	active	hormones	that	exert	their	action	in	the	same	cells	where	synthesis	
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took	place	without	release	into	the	pericellular	compartment.”[22,23]	The	presence	of	
steroidogenic	enzymes	in	the	ocular	surface	tissues	suggests	that	human	ocular	surface	
tissues	are	capable	of	local	formation	as	well	as	inactivation	of	sex	steroids.	The	
presence	of	AR,	ER	and/or	PR	mRNA	and	protein	suggests	that	these	ocular	tissues	are	
target	sites	for	sex	hormones	and	that	once	synthesized,	the	locally	produced	sex	
steroids	may	exert	their	action	within	the	same	tissues.	This	is	supported	by	human	and	
mice	studies	which	have	demonstrated	that	androgens	and	estrogens	regulate	
numerous	genes	in	the	meibomian	gland,	lacrimal	gland	and	conjunctiva.		
The	important	physiological	role	of	estrogens	and	androgens	in	the	function	and	
structure	of	ocular	tissues	calls	for	an	improved	understanding	of	intracrine	hormone	
synthesis	and	their	metabolism.	Measurement	of		local	sex	hormone	levels	has	its	
challenges,	including	the	procurement	of	human	ocular	surface	tissue.	Measuring	levels	
of	sex	hormones	and	metabolites	in	tears	or	meibum	thus	provides	an	estimateof	ocular	
surface	tissue	levels,	without	the	need	for	tissue	excision.	Technological	advances,	
including	in	LC‐MS	and	GC‐MS,	will	provide	the	sensitivity	required	to	measure	the	low	
levels	of	sex	hormones	and	their	metabolites	which	are	present	in	human	tears	and	
meibum.	
Developments	in	technology	not	only	allow	our	understanding	of	how	sex	hormones	
influence	the	ultrastructure	of	ocular	tissues,	but	also	uncover	the	presence	of	the	
biological	machinery	needed	for	intracrine	hormone	synthesis.	Thus	it	is	anticipated	
that	with	further	technological	developments,	rapid	progress	will	be	made	in	
understanding	how	sex	hormones	affect	ocular	tissues	and	contribute	to	the	
development	of	dry	eye.	Clarification	of	the	action	of	sex	hormones	on	ocular	surface	
tissues	and	their	contribution	to	dry	eye	is	essential	for	the	development	of	suitable	
hormone	based	treatments	for	dry	eye.	
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FIG	1:	Schematic	representation	of	human	endocrine	(adrenal)	and	intracrine	
steroidogenic	pathways.	Endocrine	processes	allow	cholesterol	to	be	converted	
into	progestagens	then	androgens,	which	are	then	transformed	into	estrogens.	
DHEA	and	DHEAS	are	secreted	by	the	adrenals	and	are	used	for	steroidogenesis	
in	peripheral	intracrine	tissues.	Corticosteroids	are	also	included	as	they	are	
formed	from	the	same	precursors	(progesterone	and	17α‐hydroxyprogesterone).	
Corticosteroids	include	mineralocorticoids	(primary	being	aldosterone)	and	
glucocorticoids	(primary	being	cortisol).Italic	boxes	represent	enzymes	involved.	
Adapted	from	Labrie	2007.[28]	
Abbreviations:	DHEA:	dehydroepiandrosterone,	DHEAS:	
dehydroepiandrosterone‐sulphate,	DHT:	dihydrotestosterone	
	
FIG	2:	Schematic	representation	of	ovarian	and	adrenal	sources	of	sex	steroids	in	
premenopausal	women.	Humans	have	adrenal	glands	which	secrete	large	
quantities	of	the	precursor	DHEA	which	is	converted	into	progestogens,	
androgens	and	estrogens	in	peripheral	tissues.	After	menopause	ovarian	estradiol	
secretion	ceases,	thus	100%	of	sex	steroids	are	then	made	locally	in	tissues	by	
intracrine	pathways.	LH	stimulates	the	secretion	of	sex	hormones	from	the	
gonads	and	ACTH	modulates	adrenal	secretion	of	DHEA.		
Adapted	from	Labrie	2003.	[30]	
Abbreviations:	LH:	Luteinising	hormone,	ACTH:	adrenocorticotropin,	DHEA:	
dehydroepiandrosterone.	
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